Evidence map›Paper›PMID 20531015›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2010

Effect of host genetics on incidence of HIV neuroretinal disorder in patients with AIDS.

Efe Sezgin, Sher L Hendrickson, Douglas A Jabs, Mark L Van Natta, Richard A Lewis, Jennifer L Troyer, Stephen J O'Brien, SOCA Research Group

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00000168 (Studies of Ocular Complications of AIDS), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000168 completednot on this map

Studies of Ocular Complications of AIDS (SOCA)

TypeobservationalSponsorJohns Hopkins Bloomberg School of Public HealthRan1998 to 2013Enrolled2,392ConditionsHIV Infections, Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Evaluation of hepatitis C virus as a risk factor for HIV-associated neuroretinal disorder.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Efe SezginLaboratory of Genomic Diversity, National Cancer Institute, Frederick, MD 21702-1201, USA. sezginef@mail.nih.gov
Sher L Hendrickson
Douglas A Jabs
Mark L Van Natta
Richard A Lewis
Jennifer L Troyer
Stephen J O'Brien
SOCA Research Group
Johns Hopkins University · USNational Cancer Institute · USBaylor College of Medicine · USFrederick National Laboratory for Cancer Research · US

Funding

Studies of Ocular Complications of AIDS - Coordinating CenterU10EY008057 · NEI · JOHNS HOPKINS UNIVERSITY · PI VAN NATTA, MARK L · 1988 to 2012
$78.0M
ZOPOLRESTAT IN NORMOTENSIVE, TYPE 1 DIA WITH INCIPIENT NEPHROPATHYM01RR000043 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZAIA, JOHN A · 1985 to 2010
$76.4M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024996 · NCRR · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2007 to 2011
$49.6M
ZDV &3TC NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFECTED INFANTS &M01RR000865 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WASHINGTON, ARNOLD E. · 1985 to 2011
$43.4M
Zonisamide in Patients with Neuropathic Pain Associated with Diabetic NeuropathyM01RR000046 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOY, MELANIE S · 1985 to 2008
$38.5M
ZOPOLRESTAT IN SUBJECTS W/ PERIPHERAL SYMMETRICAL DIABETIC POLYNEUROPATHYM01RR000096 · NCRR · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NOVIK, YELENA · 1985 to 2008
$34.8M
ZENARESTAT IN DIABETIC NEUROPATHYM01RR005096 · NCRR · TULANE UNIVERSITY OF LOUISIANA · PI FONSECA, VIVIAN A · 1990 to 2006
$17.4M
WOMEN'S HEALTH AGENDAU01AI025868 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ERON, JOSEPH J. · 1987 to 2006
$14.9M
WOMEN'S HEALTH AGENDAU01AI027670 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BENSON, CONSTANCE ANN · 1988 to 2006
$13.7M
WOMEN'S HEALTH AGENDAU01AI032783 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI TEBAS, PABLO · 1992 to 2007
$11.9M
WOMEN'S HEALTH AGENDAU01AI027660 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CURRIER, JUDITH S. · 1988 to 2006
$11.8M
WOMEN'S HEALTH AGENDAU01AI027663 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 1988 to 2006
$11.4M
Intramural NIH HHS Z99 CA999999NCI NIH HHS N01 CO012400NCI NIH HHS N01-CO-12400NCRR NIH HHS M01 RR000043NCRR NIH HHS M01 RR000046NCRR NIH HHS M01 RR000096NCRR NIH HHS M01 RR000865NCRR NIH HHS M01 RR005096NCRR NIH HHS UL1 RR024996NEI NIH HHS U10 EY008052NEI NIH HHS U10 EY008057NEI NIH HHS U10 EY008067NEI NIH HHS U10-EY-08052NEI NIH HHS U10-EY-08057NEI NIH HHS U10-EY-08067NIAID NIH HHS U01 AI025868NIAID NIH HHS U01 AI027660NIAID NIH HHS U01 AI027663NIAID NIH HHS U01 AI027670NIAID NIH HHS U01 AI032783PHS HHS HHSN26120080001E
6 · The paper itself

Abstract

Approximately 10%-15% of patients with AIDS but without ocular opportunistic infections will have a presumed neuroretinal disorder (HIV-NRD), manifested by reduced contrast sensitivity and abnormal visual fields. The loss of contrast sensitivity often is sufficient to impair reading speed. To evaluate the effect of host genetics on HIV-NRD, we explored validated AIDS restriction gene variants CCR5Delta32, CCR2-64I, CCR5 P1, SDF-3'A, IL-10-5'A, RANTES -403A, RANTES -28G, RANTES-In1.1C, CX3CR1-249I, CX3CR1-280M, IFNG-179T, MDR1-3435T, and MCP-1364G, each of which has been implicated previously to influence HIV-1 infection, AIDS progression, therapy response, and antiviral drug metabolism, and an IL-10 receptor gene, IL-10R1, in the Longitudinal Study of the Ocular Complications of AIDS cohort. In European Americans (cases = 55, controls = 290), IL-10-5'A variant and its promoter haplotype (hazard ratio = 2.09, confidence interval. 1.19 to 3.67, P = 0.01), in African Americans (cases = 54, controls = 180), RANTES-In1.1C and the associated haplotype (hazard ratio = 2.72, confidence interval.: 1.48 to 5.00, P = 0.001), showed increased HIV-NRD susceptibility. Although sample sizes are small and P values do not pass a strict Bonferroni correction, our results suggest that, in European Americans, an IL-10-related pathway, and, in African Americans, chemokine receptor ligand polymorphisms in RANTES are risk factors for HIV-NRD development. Clearly, further studies are warrented.

Indexed as

Acquired Immunodeficiency SyndromeAdultCD4 Lymphocyte CountChemokine CCL5Disease ProgressionFemaleGenetic Predisposition to DiseaseGenetic VariationGenotypeHaplotypesHIV InfectionsHumansLongitudinal StudiesMaleMiddle AgedReceptors, CCR2CCL5 protein, humanCCR2 protein, humanChemokine CCL5Receptors, CCR2Receptors, CCR5

Identifiers

PMID20531015
PMCPMC2908809
OpenAlexW2082453534

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.